Eflapegrastim is novel long-acting granulocyte-colony stimulating factor therapy. Pharmacokinetic analysis in vivo demonstrated a 2- to 3-fold increase in area under the time‐concentration curve for absolute neutrophil count versus pegfilgrastim when administered at similar doses, and the proposed drug demonstrated comparable efficacy compared with pegfilgrastim in an open-label study in patients with breast cancer who were receiving docetaxel and cyclophosphamide.
While no biosimilar developer has gained regulatory approval for a pegfilgrastim biosimilar in the United States or the European Union, numerous companies are targeting the drug, and some hope to gain approvals and even launch products later this year. However, even as competition from biosimilars approaches, a novel granulocyte-colony stimulating factor (G-CSF) drug could also compete with the reference pegfilgrastim, Neulasta.
Eflapegrastim is novel long-acting granulocyte-colony stimulating factor therapy. Pharmacokinetic analysis in vivo demonstrated a 2- to 3-fold increase in area under the time‐concentration curve for absolute neutrophil count versus pegfilgrastim when administered at similar doses, and the proposed drug demonstrated comparable efficacy compared with pegfilgrastim in an open-label study in patients with breast cancer who were receiving docetaxel and cyclophosphamide.
The study, published last week in Cancer Medicine, was designed to evaluate the efficacy and safety of the eflapegrastim at 3 dose levels, and its primary efficacy endpoint was the duration of severe neutropenia during the first cycle of chemotherapy. In total, 148 patients were enrolled between 2013 and 2014 in 27 sites in 6 countries, and 147 patients were evaluable. Patients were given eflapegrastim at a dose of 45 μg/kg (n = 39), 135 μg/kg (n = 36), or 270 μg/kg (n = 36), or pegfilgrastim (n = 36).
Overall, 138 patients (93%) completed all 4 cycles of chemotherapy, and the following were observed across the 4 groups:
The rate of hospitalizations across all cycles was similar across treatment groups, with the highest incidence observed in the pegfilgrastim group (14%) and the lowest incidence observed in the group receiving the highest dose of eflapegrastim (3%).
Across all groups, 89% of patients experienced adverse events (AEs). The most commonly reported AEs, most of which were mild to moderate, were fatigue, alopecia, nausea, diarrhea, and bone pain. No neutralizing antibodies against eflapegrastim were detected in this study.
The authors concluded that eflapegrastim had comparable efficacy to pegfilgrastim on the duration of severe neutropenia, and that the proposed drug presented no new safety concerns.
Spectrum Pharmaceuticals, which is developing eflapegrastim, plans to submit a Biologics License Application to the FDA later this year.
Reference
Vacira JL, Chan A, Mezei K, et al. An open‐label, dose‐ranging study of Rolontis, a novel long‐acting myeloid growth factor, in breast cancer. Cancer Med-US. Published online March 23, 2018. https://doi.org/10.1002/cam4.1388.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.